| Schedule of financial data for the one reportable segment |
| | | | | | | | | | | | | | | Three Months Ended | | Six Months Ended | | | June 30, | | June 30, | | | 2025 | | 2024 | | 2025 | | 2024 | Research and development: | | | | | | | | | | | | | Phase 2 study in WM | | $ | 495,000 | | $ | 2,791,000 | | $ | 1,128,000 | | $ | 4,985,000 | Phase 1 study in pediatric tumors | | | 243,000 | | | 1,160,000 | | | 976,000 | | | 1,659,000 | Manufacturing and related costs | | | 871,000 | | | 2,628,000 | | | 1,580,000 | | | 5,941,000 | Pre-clinical projects cost | | | 145,000 | | | 31,000 | | | 652,000 | | | 52,000 | General research and development costs | | | 636,000 | | | 735,000 | | | 1,481,000 | | | 1,797,000 | General and administrative | | | 3,648,000 | | | 6,358,000 | | | 6,622,000 | | | 11,272,000 | Other segment items | | | (590,000) | | | (12,784,000) | | | (387,000) | | | 1,856,000 | Segment and consolidated net loss | | $ | 5,448,000 | | $ | 919,000 | | $ | 12,052,000 | | $ | 27,562,000 |
|